Israel News App
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan – Biogen
Written by
admin
in
6. Business
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
Biogen
Biogen (BIIB) Advances Alzheimer’s Treatment with FDA Submission
GuruFocus
Eisai (TSE:4523):…
Continue Reading